Kronos Bio Stock
Kronos Bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets.
Sign up today and learn more about Kronos Bio Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Kronos Bio Stock
Kronos Bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling. . In 2017, Angela Koehler, Christopher Wilfong, and Joshua A. Kazam established Kronos Bio in San Mateo California.
Funding History
| June 2018 | $18.0M |
|---|---|
| July 2019 | $105M |
Management
Vice President, Program Management
Christopher Lee
Vice President, Pharmacology
Douglas C. Saffran
President & Chief Executive Officer
Norbert Bischofberger
Chief Operating Officer and Founder
Christopher Wilfong
Vice President, Clinical Operations
Zung To
Vice President, Biology
Charles Lin
Vice President, Chemistry
Wes Trotter
Scientific Founder
Angela Koehler
Chief Medical Officer & Executive Vice President, Clinical Development
Jorge DiMartino
Chief Business Officer
Philip P. Gutry
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
